Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

EQS-Adhoc: Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide

eqs_en 
0 0 05.12.23
EQS-Adhoc: Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/23622/Logo_Merck_KGaA_2015.svg.png
 

EQS-Ad-hoc: Merck KGaA / Key word(s): Study results
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide

05-Dec-2023 / 21:34 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Darmstadt, 5 December 2023: Merck KGaA is investigating a highly selective oral and central nervous system penetrant Bruton’s tyrosine kinase inhibitor (BTKi) as a potential treatment for relapsing multiple sclerosis ("RMS") in two pivotal phase III clinical trials (evolutionRMS 1 and evolutionRMS 2, together the "Clinical Trials"). Both Clinical Trials, evaluating the efficacy and safety of evobrutinib compared to teriflunomide for up to 156 weeks, did not meet the primary endpoint of reducing annualized relapse rates (ARR) in people with RMS.

Evobrutinib is currently under clinical investigation and not approved for any use anywhere in the world.


Contact:
Esther Döringer
Merck KGaA
Frankfurter Straße 250
64293 Darmstadt
Germany
Phone: +49 151 1454 7809
Email: [email protected]
Internet: https://www.merckgroup.com/en
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Stock exchanges: Regulated Market of Frankfurt am Main (Prime Standard); Open Markets of Berlin, Düsseldorf, Hamburg, Hanover, Munich, Stuttgart; EUREX derivatives exchange; London, SIX


End of Inside Information

05-Dec-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
Language: English
Company: Merck KGaA
Frankfurter Str. 250
64293 Darmstadt
Germany
Phone: +49 (0)6151 72 - 2702
E-mail: [email protected]
Internet: https://www.merckgroup.com/de
ISIN: DE0006599905
WKN: 659990
Indices: DAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; London, SIX
EQS News ID: 1790011

 
End of Announcement EQS News Service

1790011  05-Dec-2023 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1790011&application_name=news&site_id=sharewise

Merck KGaA Stock

€150.00
-2.100%
We can see a decrease in the price for Merck KGaA. Compared to yesterday it has lost -€3.200 (-2.100%).
Currently there is a rather positive sentiment for Merck KGaA with 3 Buy predictions and 1 Sell predictions.
On the other hand, the target price of 146 € is below the current price of 150.0 € for Merck KGaA, so the potential is actually -2.67%.
Show more
Like: 0
Share
eqs_en 
EQS Group is a leading international provider of regulatory technology in the fields of corporate compliance and investor relations. In working with EQS Group, thousands of companies worldwide inspire trust by fulfilling complex national and international disclosure obligations, minimizing risks and communicating transparently with stakeholders.




Legal notice

Comments

Not a member yet? Sign up for free!